Treatment Posts on Medivizor
Navigation Menu

Treatment Posts on Medivizor

Does metformin use decrease the risk of hospitalization and mortality from COVID-19?

Does metformin use decrease the risk of hospitalization and mortality from COVID-19?

Posted by on May 8, 2022 in Diabetes mellitus | 0 comments

In a nutshell This study assessed the link between metformin (Glucophage) use in hospitalized and non-hospitalized patients with diabetes and different outcomes due to coronavirus disease 2019 (COVID-19). The study showed that metformin use was associated with a protective effect in COVID-19 outcomes in patients with type 2 diabetes (T2D). Some...

Read More

Evaluating the effectiveness and safety of an all-oral combination of ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma undergoing stem cell transplantation.

Evaluating the effectiveness and safety of an all-oral combination of ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma undergoing stem cell transplantation.

Posted by on May 8, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of an all-oral combination of ixazomib (Ninlaro), lenalidomide (Revlimid), and dexamethasone (Decadron) in transplant-eligible patients with newly diagnosed multiple myeloma (MM). The data showed that this combination was effective with manageable side effects in these...

Read More

Evaluating the long-term effectiveness and safety of adding carboplatin with or without veliparib to standard chemotherapy given before surgery in patients with triple‑negative breast cancer.

Evaluating the long-term effectiveness and safety of adding carboplatin with or without veliparib to standard chemotherapy given before surgery in patients with triple‑negative breast cancer.

Posted by on May 8, 2022 in Breast cancer | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of adding carboplatin (Paraplatin) with or without veliparib (ABT-888) to standard chemotherapy given before surgery (neoadjuvant chemotherapy; NACT) in patients with early-stage triple-negative breast cancer (TNBC). The data showed that the addition of carboplatin to standard NACT...

Read More

Is clopidogrel better than ticagrelor in reducing bleeding in stabilized patients with myocardial infarction undergoing percutaneous coronary intervention ?

Is clopidogrel better than ticagrelor in reducing bleeding in stabilized patients with myocardial infarction undergoing percutaneous coronary intervention ?

Posted by on May 8, 2022 in Coronary artery disease | 0 comments

In a nutshell This study investigated if de-escalation (reducing the intensity) of dual antiplatelet therapy (DAPT) with clopidogrel (Plavix) might be better than ticagrelor (Brilique)-based antiplatelet therapy in stabilized patients with acute myocardial infarction (MI; heart attack) undergoing percutaneous coronary intervention (PCI). The data...

Read More

Evaluating the safety and effectiveness of pembrolizumab in combination with rituximab in patients with relapsed or refractory follicular lymphoma.

Evaluating the safety and effectiveness of pembrolizumab in combination with rituximab in patients with relapsed or refractory follicular lymphoma.

Posted by on May 8, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of pembrolizumab (Keytruda) in combination with rituximab (Rituxan) in patients with relapsed or refractory (r/r) follicular lymphoma (FL). The data showed that pembrolizumab in combination with rituximab was safe and effective in these patients. Some background Follicular lymphoma (FL)...

Read More

Comparing the effectiveness and safety of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

Comparing the effectiveness and safety of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

Posted by on May 8, 2022 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of abiraterone acetate (Zytiga; AA) and enzalutamide (Xtandi; ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that both medication improve outcomes compared to placebo and ENZ is more effective in improving survival without cancer...

Read More

Evaluating the effectiveness and safety of sugemalimab plus platinum-based chemotherapy for first-line treatment of metastatic squamous and non-squamous non-small cell lung cancer.

Evaluating the effectiveness and safety of sugemalimab plus platinum-based chemotherapy for first-line treatment of metastatic squamous and non-squamous non-small cell lung cancer.

Posted by on May 8, 2022 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of sugemalimab (Cejemly) in combination with platinum-based chemotherapy as first-line treatment for patients with metastatic squamous (Sq) and non-squamous (non-Sq) non-small cell lung cancer (NSCLC). The data showed that sugemalimab plus platinum-based chemotherapy...

Read More

How effective is denosumab treatment in patients with rheumatoid arthritis?

How effective is denosumab treatment in patients with rheumatoid arthritis?

Posted by on Apr 29, 2022 in Rheumatoid Arthritis | 0 comments

In a nutshell This review evaluated the effectiveness of denosumab (Prolia) on bone mineral density (BMD) and joint destruction in patients with rheumatoid arthritis (RA). The authors concluded that denosumab treatment was linked to increased BMD and reduced joint destruction in patients with RA. Some background RA is a chronic inflammatory...

Read More

Evaluating the effectiveness and safety of ixazomib-dexamethasone versus pomalidomide-dexamethasone combination for the treatment of patients with relapsed or refractory multiple myeloma.

Evaluating the effectiveness and safety of ixazomib-dexamethasone versus pomalidomide-dexamethasone combination for the treatment of patients with relapsed or refractory multiple myeloma.

Posted by on Apr 29, 2022 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of ixazomib (Ninlaro)-dexamethasone (Decadron) (ixa-dex) versus pomalidomide (Pomalyst)-dexamethasone (pom-dex) combination for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). The data showed that ixa-dex was safe and as effective as pom-dex...

Read More

Comparing the effectiveness and safety of avanafil and sildenafil for the treatment of patients with erectile dysfunction.

Comparing the effectiveness and safety of avanafil and sildenafil for the treatment of patients with erectile dysfunction.

Posted by on Apr 26, 2022 in Erectile dysfunction | 0 comments

In a nutshell This study compared the effectiveness and safety of avanafil (Stendra) with sildenafil (Viagra) for the treatment of patients with erectile dysfunction (ED). The data showed that avanafil had higher effectiveness compared to sildenafil in improving the symptoms of ED after 12 weeks. Some background Erectile dysfunction...

Read More

Comparing the effectiveness and safety between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma.

Comparing the effectiveness and safety between R-CHOP and modified NHL-BFM-90 regimens in children and adolescents with diffuse large B-cell lymphoma.

Posted by on Apr 26, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness and safety of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) and modified non-Hodgkin lymphoma (NHL) Berlin-Frankfurt-Münster-90 (NHL-BFM-90; cyclophosphamide, vincristine, ifosfamide, etoposide, adriamycin, methotrexate, vindesine, dexamethasone, cytarabine)...

Read More

Long-term safety and effectiveness of acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in patients with chronic lymphocytic leukemia

Long-term safety and effectiveness of acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in patients with chronic lymphocytic leukemia

Posted by on Apr 26, 2022 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term safety and effectiveness of acalabrutinib (Calquence) with or without obinutuzumab (Gazyva) versus obinutuzumab with chlorambucil (Leukeran) in patients with chronic lymphocytic leukemia (CLL) that have never received treatment (treatment-naive).  This study concluded that the...

Read More